Plasmatic concentrations of fluoxetine and clinical improvement in patients with Major Depressive Disorder, Obsesive-Compulsive Disorder and Generalized Anxiety Disorder

Downloads

Published

2013-03-12

How to Cite

Blázquez Hinojosa, A., Mas Herrero, S., Plana Turró, M., Lafuente Flo, A., Méndez Blanco, I., & Lázaro García, L. (2013). Plasmatic concentrations of fluoxetine and clinical improvement in patients with Major Depressive Disorder, Obsesive-Compulsive Disorder and Generalized Anxiety Disorder. Revista De Psiquiatría Infanto-Juvenil, 30(1), 49–54. Retrieved from https://aepnya.eu/index.php/revistaaepnya/article/view/264

Issue

Vol. 30 No. 1 (2013)

Section

Orginial article

Authors

  • A. Blázquez Hinojosa Hospital Clínic i Provincial
  • S. Mas Herrero Hospital Clínic i Provincial
  • MT. Plana Turró Hospital Clínic i Provincial
  • A. Lafuente Flo Hospital Clínic i Provincial
  • I. Méndez Blanco Hospital Clínic i Provincial
  • L. Lázaro García Hospital Clínic i Provincial

Keywords:

adolescents, pharmacokinetics, major depression disorder, obsessive compulsive disorder, generalized anxiety disorder

Abstract

Introduction: Although fluoxetine is a useful drug in the treatment of major depression disorder (MDD), obsessive compulsory disorder (OCD) and generalized anxiety disorder (GAD) in adolescents, a percentage of the patients do not respond to treatment.

Aim: Determine if clinical improvement is related to plasma concentration of fluoxetine at 8 and 12 weeks after starting treatment.

Materials and Methods: The study was carried out in children and adolescents treated with fluoxetine and with diagnoses of MDD, OCD, or GAD. The period of recruitment was from June to December 2011. To assess clinical improvement CDI, SCARED, OCI and CGI scales were administered at weeks 0, 8, 12. UKU scale was administered to assess side effects of treatment. Spearman’s rank correlation coefficient was used to assess relationship between two variables.

Results: The sample was 18 patients. 66% diagnosed MDD, 16,7% GAD and 16,7% OCD. At week 8, a significant linear correlation between plasmatic concentrations of fluoxetine and side effects (measured by UKU scale) was found (Spearman’s rank correlation coefficient= 0.48 p= 0.044) and between plasmatic concentrations of fluoxetine and punctuation at CGI scale (Spearman’s rank correlation coefficient= 0.56 p= 0.014). At week 12, a significant linear correlation between plasmatic concentrations of fluoxetine and side effects was found (Spearman’s rank correlation coefficient= 0.49 p= 0.038) and between plasmatic concentrations of fluoxetine and punctuation at CGI scale (Spearman’s rank correlation coefficient= 0.58 p= 0.011).

Conclusions: The side effects were related to plasmatic concentrations of fluoxetine and clinical improvement.

Downloads

Download data is not yet available.

Author Biography

A. Blázquez Hinojosa, Hospital Clínic i Provincial

Correspondencia:
abhinojo@clinic.ub.es.

References

Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000; 85 (1): 11-28.

Kronenberg S, Frisch A, Rotberg B, Carmel M, Apter A, Weizman A. Pharmacogenetics of selective serotonin reuptake inhibitors in paediatric depression and anxiety. Pharmacogenomics. 2008; 9 (11): 1725-36.

Wilens TE, Cohen L, Biederman J, Abrams A, Neft D, Faird N, et al. Fluoxetine Pharmacokinetics in pediatric patients. J Clin Psychopharmacol. 2002; 22 (6): 568-75.

Findling RL, McNamara NK, Stansbrey RJ, Feeny NC, Young CM, Peric FV, et al. The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression. J Child Adolesc Psychopharmacol. 2006; 16 (1-2): 131-45.

DeVane CL. Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol. 1999; 19 (4): 443-66.

Ring BJ, Eckstein JA, Gillespie JS, Binkley SN, Vandenbranden M, Wrighton SA. Identification of the human cytochromes P450 responsibles for in vitro formation of R- and S-Norfluoxetine. J Pharmacol Exp Ther. 2001; 297: 1044-50.

Charlier C, Broly F, Lhermitte M, Pinto E, Ansseau M, Plomteaux G. Polymorphisms in the CYP2D6 Gene: Association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit. 2003; 25: 738-42.

Spina E, Santoro V, D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008; 30 (7): 1206-27.

Scordo MG, Spina E, Dahl M-L, Gatti G, Perucca E. Influence of CYP2C9, 2C19 and D6 Genetic polymorphisms on the Steady-State plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol. 2005; 97: 296-301.

Llerena A, Dorado P, Berecz R, González AP, Peñas-Lledó EM. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur J Clin Pharmacol. 2004; 59: 869-873.

Amsterdam JD, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Michelson D, et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry. 1997; 154: 963-9.

Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994; 26: 201-214.

Koelch M, Pfalzer AK, Kliegl K, Rothenhöfer S, Ludolph AG, Fegert JM, et al. Therapeutic drug monitoring of children and adolescents treated with fluoxetine. Pharmacopsychiatry. 2012; 45:72-6.

Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987; 334: 1-100.

Guy, W. ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda, MD: United States Department of Health, Education, and Welfare; 1976.

Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997; 36: 980-8.

Kovacs, M. Children’s Depression Inventory manual. New York: Multi-Health Systems; 1992.

Foa EB, Coles M, Huppert JD, Pasupuleti RV, Franklin ME, March J. Development and validation of a child version of the obsessive compulsive inventory. Behav Ther. 2010; 41:121-32.

Birmaher B, Khetarpal S, Brent D, Cully M, Balach L, Kaufman J, et al. The Screen for Child Anxiety Related Emotional Disorders (SCARED): scale construction and psychometric characteristics. J Am Acad Child Adolesc Psychiatry. 1997; 36: 545-53.

Luborsky L. Clinician’s judgments of mental health: A proposed scale. Arch Gen Psychiatry. 1962; 7: 407– 17.

Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, et al. A children’s global assessment scale (CGAS). Arch Gen Psychiatry. 1983; 40: 1228-31.

Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale–Brown Obsessive–Compulsive Scale: I. Development, use, and reliability. Archives of General Psychiatry. 1989; 46, 1006–1011.

Llerena A, Dorado P, Berecz R, González A, Jesús Norberto M, de la Rubia A, et al. Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2003; 783: 25-31.

Sakolsky DJ, Perel JM, Emslie GJ, Clarke GN, Wagner KD, Vitiello B, et al. Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study. J Clin Psychopharmacol. 2011; 31: 92-7.

Cherma MD, Ahlner J, Bengtsson F et al. Antidepressants drugs in children and adolescents, analytical and demographic data in naturalistic, clinical study. J Clin Psychopharmacol 2011; 31: 98-102.

Most read articles by the same author(s)